Observing blood biomarkers in children with amblyopia
Prognostic Value of Plasma Biomarkers Among Patients With Amblyopia
This study looks at blood samples from children with amblyopia to see if certain markers can help predict how well their treatment will work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 3 Years to 12 Years |
| Sex | All |
| Sponsor | Zhongshan Ophthalmic Center, Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05705778 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the predictive effect of plasma biomarkers on treatment outcomes in children diagnosed with amblyopia. It will involve children aged 3 to 12 years who are undergoing standard amblyopia treatment, with follow-up visits every three months. The study also seeks to explore the mechanisms of neuromodulation in the visual development of these children. By analyzing blood samples, researchers hope to identify biomarkers that can predict treatment success.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 3 to 12 years who have been diagnosed with amblyopia and can tolerate the standard treatment.
Not a fit: Patients with previous treatment history for amblyopia or those with significant ocular or neurological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for children with amblyopia.
How similar studies have performed: While there is ongoing research into biomarkers for various conditions, this specific approach in amblyopia treatment is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with amblyopia * 3-12 years of age * Able to tolerate amblyopia treatment * Agree to be involved in this study and agree to have a follow up visit every 3 months. Exclusion Criteria: * Have previous treatment history before * Have pathological ocular anomalies known to cause reduced visual acuity * Have previous psychiatric, visual or neurological disorders * Have eccentric fixation and/or abnormal retinal correspondence * Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves
Where this trial is running
Guangzhou, Guangdong
- Zhongshan Ophthalmic Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jinrong Li, PhD
- Email: lijingr3@mail.sysu.edu.cn
- Phone: 86-020-87330351
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.